Biocon Limited · NSE:BIOCON
Biocon — Q4 FY22 Earnings Presentation
22 slides from Biocon's earnings presentation, Apr 29, 2022
Slide 1: Q4 and full year FY22 Earnings Call
Q4 and full year FY22 Earnings Call April 29, 2022 B I O C O N L I M I T E D 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 3: Q4 and full year FY22 Earnings Call
Q4 and full year FY22 Earnings Call B I O C O N L I M I T E D 3
Slide 4: Opening Remarks
Opening Remarks Biocon reported revenues of $1.1 billion (₹8,397 Crores) Transformative acquisition of Viatris’ biosimilars business for $3.335 billion Biocon awarded by EcoVadis in the ‘Bronze’ category for its sustainability practices B I O C O N L I M I T E D 4
Slide 5: 'Pipeline is our lifeline'
‘Pipeline is our lifeline’ GENERICS APIs Formulations Niche Device Potent Peptide molecules Potent Oral Injectables Topicals Dependent APIs APIs for Solids Products hospitals BIOSIMILARS Today < 2 years 2-4 years >4 years - Pegfilgrastim - Bevacizumab (US) - Aflibercept2 - Pertuzumab - Trastuzumab -
Slide 6: Board Update
Board Update B I O C O N L I M I T E D 6
Slide 7: Board Update
Board Update Naina Lal Kidwai joins Biocon Limited Board as Additional Director - A veteran banker and business leader - Past President of FICCI - An MBA from Harvard Business School - Recipient of several awards including the Padma Shri for her contribution to trade & industry. - Serves as an Addit
Slide 8: Financial Highlights Q4 and full year FY22
Financial Highlights Q4 and full year FY22 B I O C O N L I M I T E D 8
Slide 9: Financial Highlights: Q4FY22
Financial Highlights: Q4FY22 Q4FY22 Q4FY21 Biosimilars +48% | Generics +26% | Research Services +15% Revenue +21% ₹2,476Cr ₹2,048Cr Dilution Gain in Bicara of ₹30Cr vs ₹160Cr in Q4FY21 Core EBITDA* +37% ₹815Cr ₹594Cr Mark-to-market loss on investments of ₹6Cr % margin 33% 32% Forex Gain of ₹2Cr vs ₹
Slide 10: Financial Highlights: FY22
Financial Highlights: FY22 FY22 FY21 Biosimilars +24% | Research Services +19% | Generics -1% Revenue +14% ₹8,397Cr ₹7,398Cr Dilution Gain in Bicara of ₹30Cr vs ₹160Cr in FY21 Core EBITDA* +18% ₹2,669Cr ₹2,270Cr Mark-to-market loss on investments of ₹28Cr; Forex Gain of ₹58Cr vs loss of ₹9Cr % margi
Slide 11: Generics Q4 and full year FY22
Generics Q4 and full year FY22 B I O C O N L I M I T E D 11
Slide 12: Generics: Q4FY22 and full year FY22
Generics: Q4FY22 and full year FY22 KEY Q4 HIGHLIGHTS Q4FY22 Q4FY21 Revenue Robust sequential and YoY growth in Q4 driven by API sales ramp ₹717Cr ₹570Cr +26% up, new launches in the US & normalization of operations Profit Before Tax (PBT) Posaconazole and Dorzolamide, launched in the US; 1st MoW ma
Slide 13: Biosimilars Q4 and full year FY22
Biosimilars Q4 and full year FY22 B I O C O N L I M I T E D 13
Slide 14: Biosimilars: Q4 and full year FY22 Financials
Biosimilars: Q4 and full year FY22 Financials Q4 FY22 Q4 FY21 FY22 FY21 Revenue ₹982Cr ₹664Cr +48% ₹3,464Cr ₹2,800Cr +24% Core EBITDA* ₹382Cr ₹215Cr +78% ₹1,320Cr ₹1,010Cr +30% % margin 39% 33% 39% 36% Profit Before Tax ₹144Cr ₹69Cr +109% ₹543Cr ₹365Cr +49% before Exceptional Items % margin 15% 10%
Slide 15: Biosimilars: Key Highlights
Biosimilars: Key Highlights COMMERCIAL PERFORMANCE P I P E L I N E U P D AT E S Interchangeable bGlargine to potentially end CY 2022 Unpartnered wave 2 programs, bDenosumab and with mid to high teens market share bUstekinumab, entered clinical development Oncology franchise continues strong performa
Slide 16: Novels Q4FY22
Novels Q4FY22 B I O C O N L I M I T E D 16
Slide 17: Novels: Q4FY22
Novels: Q4FY22 KEY HIGHLIGHTS Pivotal Phase III clinical study of Itolizumab for aGVHD* initiated in March 2022 Bicara# initiated dose expansion cohorts evaluating BCA101 in patients with head and neck, anal canal & cutaneous squamous cell carcinoma *Acute Graft-Versus-Host Disease #In Q4FY21, Bioco
Slide 18: Research Services Q4 and full year FY22
Research Services Q4 and full year FY22 B I O C O N L I M I T E D 18
Slide 19: Research Services: Q4FY22 and full year FY22
Research Services: Q4FY22 and full year FY22 KEY Q4 HIGHLIGHTS Q4FY22 Q4FY21 Revenue ₹758Cr ₹659Cr +15% Performance across all divisions in Q4 Profit Before Tax (PBT) ₹179Cr ₹158Cr +14% Particularly strong quarter for Development Services on account of 24% of revenue 24% of revenue catching up on ea
Slide 20: Concluding Remarks
Concluding Remarks B I O C O N L I M I T E D 20
Slide 21: Concluding Remarks
Concluding Remarks Final Dividend of 10% of face value of each share proposed for FY22 Viatris and Serum deals to drive FY23 Growth B I O C O N L I M I T E D 21
Slide 22: Q&A
Q&A B I O C O N L I M I T E D 22